Paclitaxel, Ifosfamide, and Cisplatin in Patients with Poor-prognosis Disseminated Nonseminomatous Germ Cell Tumors with Unfavorable Serum Tumor Marker Decline After First Cycle of Chemotherapy. The GCT-SK-003 Phase II Trial-Reference-Cited by-同舟云学术

Paclitaxel, Ifosfamide, and Cisplatin in Patients with Poor-prognosis Disseminated Nonseminomatous Germ Cell Tumors with Unfavorable Serum Tumor Marker Decline After First Cycle of Chemotherapy. The GCT-SK-003 Phase II Trial

Published:2021-11 Issue: Volume:33 Page:19-27
ISSN:2666-1683
Container-title:European Urology Open Science
language:en
Short-container-title:European Urology Open Science

Author:

Mego Michal,Rejlekova Katarina,Svetlovska Daniela,Miskovska Vera,Gillis Ad J.M.,De Angelis Valentina,Kalavska Katarina,Obertova Jana,Palacka Patrik,Reckova Maria,Sycova-Mila Zuzana,Pindak Daniel,Chovanec Michal,Looijenga Leendert H.J.,Mardiak Jozef

Funder

Vedecká Grantová Agentúra MŠVVaŠ SR a SAV

Ministerio de Sanidad, Consumo y Bienestar Social

Agentúra na Podporu Výskumu a Vývoja

Publisher

Elsevier BV

Subject

Urology

Reference35 articles.

1. Cancer statistics, 2019;Siegel;CA Cancer J Clin,2019

2. Treatment of testicular cancer: a new and improved model;Einhorn;J Clin Oncol,1990

3. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers;International Germ Cell Cancer Collaborative Group;J Clin Oncol,1997

4. Predicting outcomes in men with metastatic nonseminomatous germ cell tumors (NSGCT): results from the IGCCCG Update Consortium;Gillessen;J Clin Oncol,2021

5. Testicular cancer as a model for a curable neoplasm: the Richard and Hinda Rosenthal Foundation award lecture;Einhorn;Cancer Res,1981

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. DNA damage levels in peripheral blood mononuclear cells before and after first cycle of chemotherapy have comparable prognostic values in germ cell tumor patients;Frontiers in Oncology;2024-03-01

2. Paclitaxel, ifosfamide, cisplatin (TIP) for the treatment of intermediateand poor-risk nonseminomatous germ cell tumors with an inadequate decrease in tumor markers: a phase II study;Malignant tumours;2022-07-19